{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T02:23:50Z","timestamp":1794104630980,"version":"4.8.0"},"reference-count":102,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA051008"],"award-info":[{"award-number":["P30CA051008"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA051008"],"award-info":[{"award-number":["P30CA051008"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["RM1NS133003"],"award-info":[{"award-number":["RM1NS133003"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["RM1NS133003"],"award-info":[{"award-number":["RM1NS133003"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["IRG-23-1156148-27-IRG"],"award-info":[{"award-number":["IRG-23-1156148-27-IRG"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["#2138259, #2138286, #2138307, #2137603, and #2138296."],"award-info":[{"award-number":["#2138259, #2138286, #2138307, #2137603, and #2138296."]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Glioblastoma (GBM) remains the most common and lethal adult malignant primary brain cancer with few treatment options. A significant issue hindering GBM therapeutic development is intratumor heterogeneity and plasticity. GBM tumors contain neoplastic cells within a fluid spectrum of diverse transcriptional states. Identifying effective therapeutics requires a platform that predicts the differential sensitivity and resistance of these states to various treatments. Here, we develop scFOCAL (\n                    <jats:bold>S<\/jats:bold>\n                    ingle-\n                    <jats:bold>C<\/jats:bold>\n                    ell\n                    <jats:bold>F<\/jats:bold>\n                    ramework for -\n                    <jats:bold>O<\/jats:bold>\n                    mics\n                    <jats:bold>C<\/jats:bold>\n                    onnectivity and\n                    <jats:bold>A<\/jats:bold>\n                    nalysis via\n                    <jats:bold>L<\/jats:bold>\n                    1000), to quantify the cellular drug sensitivity and resistance landscape. Using single-cell RNA sequencing of newly diagnosed and recurrent GBM tumors, we identify compounds from the LINCS L1000 database with transcriptional response signatures selectively discordant with distinct GBM cell states, and leverage this capability to predict combination synergy. We validate the significance of these findings in vitro, ex vivo, and in vivo, and identify a combination of an OLIG2 inhibitor and Depatux-M for the treatment of GBM. Our studies suggest that scFOCAL identifies cell states that are sensitive and resistant to targeted therapies in GBM using a measure of cell and drug connectivity, which can be applied to identify new synergistic combinations.\n                  <\/jats:p>","DOI":"10.1038\/s41467-025-67783-5","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T10:03:17Z","timestamp":1767780197000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Drug and single-cell gene expression integration identifies sensitive and resistant glioblastoma cell populations"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3335-8426","authenticated-orcid":false,"given":"Robert K.","family":"Suter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna M.","family":"Jermakowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rithvik","family":"Veeramachaneni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1837-7004","authenticated-orcid":false,"given":"Matthew","family":"D\u2019Antuono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1155-4171","authenticated-orcid":false,"given":"Longwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishika","family":"Chowdary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4449-6952","authenticated-orcid":false,"given":"Simon","family":"Kaeppeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madison","family":"Sharp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pravallika","family":"Palwai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasileios","family":"Stathias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luz","family":"Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winston","family":"Walters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Cepero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Burgenske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward B.","family":"Reilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anatol","family":"Oleksijew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark G.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sion Ll.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4798-4989","authenticated-orcid":false,"given":"Michael E.","family":"Ivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo J.","family":"Komotar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Macarena I.","family":"De La Fuente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3588-8834","authenticated-orcid":false,"given":"Gregory","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Wojcinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santosh","family":"Kesari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7489-4885","authenticated-orcid":false,"given":"Jann N.","family":"Sarkaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7180-0978","authenticated-orcid":false,"given":"Stephan C.","family":"Sch\u00fcrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagi G.","family":"Ayad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,7]]},"reference":[{"key":"67783_CR1","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","volume":"10","author":"R Stupp","year":"2009","unstructured":"Stupp, R. et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10, 459\u2013466 (2009).","journal-title":"Lancet Oncol."},{"key":"67783_CR2","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp, R. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987\u2013996 (2005).","journal-title":"N. Engl. J. Med."},{"key":"67783_CR3","unstructured":"Tamimi, A. F. & Juweid, M. Epidemiology and Outcome of Glioblastoma. In: Glioblastoma [Internet]. Chapter 8. (ed De Vleeschouwer, S.) (Brisbane (AU): Codon Publications; 2017)."},{"key":"67783_CR4","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.ccell.2020.03.007","volume":"37","author":"A Marusyk","year":"2020","unstructured":"Marusyk, A., Janiszewska, M. & Polyak, K. Intratumor heterogeneity: the rosetta stone of therapy resistance. Cancer Cell 37, 471\u2013484 (2020).","journal-title":"Cancer Cell"},{"key":"67783_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2020.105060","volume":"145","author":"RK Suter","year":"2020","unstructured":"Suter, R. K., Rodriguez-Blanco, J. & Ayad, N. G. Epigenetic pathways and plasticity in brain tumors. Neurobiol. Dis. 145, 105060 (2020).","journal-title":"Neurobiol. Dis."},{"key":"67783_CR6","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.cell.2019.06.024","volume":"178","author":"C Neftel","year":"2019","unstructured":"Neftel, C. et al. An integrative model of cellular states, plasticity, and genetics for glioblastoma. Cell 178, 835\u2013849.e821 (2019).","journal-title":"Cell"},{"key":"67783_CR7","doi-asserted-by":"publisher","unstructured":"Couturier, C. P. et al. Single-cell RNA-seq reveals that glioblastoma recapitulates a normal neurodevelopmental hierarchy. Nat. Commun. 11. https:\/\/doi.org\/10.1038\/s41467-020-17186-5 (2020).","DOI":"10.1038\/s41467-020-17186-5"},{"key":"67783_CR8","doi-asserted-by":"publisher","unstructured":"Dirkse, A. et al. Stem cell-associated heterogeneity in Glioblastoma results from intrinsic tumor plasticity shaped by the microenvironment. Nat. Commun. 10. https:\/\/doi.org\/10.1038\/s41467-019-09853-z (2019)","DOI":"10.1038\/s41467-019-09853-z"},{"key":"67783_CR9","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.ccell.2021.01.006","volume":"39","author":"LB Wang","year":"2021","unstructured":"Wang, L. B. et al. Proteogenomic and metabolomic characterization of human glioblastoma. Cancer Cell 39, 509\u2013528.e520 (2021).","journal-title":"Cancer Cell"},{"key":"67783_CR10","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1038\/s41591-018-0156-x","volume":"24","author":"J Klughammer","year":"2018","unstructured":"Klughammer, J. et al. The DNA methylation landscape of glioblastoma disease progression shows extensive heterogeneity in time and space. Nat. Med. 24, 1611\u20131624 (2018).","journal-title":"Nat. Med."},{"key":"67783_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms16022","volume":"8","author":"B Chen","year":"2017","unstructured":"Chen, B. et al. Reversal of cancer gene expression correlates with drug efficacy and reveals therapeutic targets. Nat. Commun. 8, 16022 (2017).","journal-title":"Nat. Commun."},{"key":"67783_CR12","doi-asserted-by":"publisher","unstructured":"Shah, A. H. et al. A multiparametric pharmacogenomic strategy for drug repositioning predicts therapeutic efficacy for glioblastoma cell lines. Neuro-Oncol. Adv. https:\/\/doi.org\/10.1093\/noajnl\/vdab192 (2021).","DOI":"10.1093\/noajnl\/vdab192"},{"key":"67783_CR13","doi-asserted-by":"publisher","unstructured":"Stathias, V. et al. Drug and disease signature integration identifies synergistic combinations in glioblastoma. Nat. Commun. 9. https:\/\/doi.org\/10.1038\/s41467-018-07659-z (2018).","DOI":"10.1038\/s41467-018-07659-z"},{"key":"67783_CR14","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.cels.2017.11.001","volume":"6","author":"AB Keenan","year":"2018","unstructured":"Keenan, A. B. et al. The library of integrated network-based cellular signatures NIH program: system-level cataloging of human cells response to perturbations. Cell Syst. 6, 13\u201324 (2018).","journal-title":"Cell Syst."},{"key":"67783_CR15","doi-asserted-by":"publisher","first-page":"5202","DOI":"10.1182\/blood-2009-12-259523","volume":"115","author":"G G\u00f6rg\u00fcn","year":"2010","unstructured":"G\u00f6rg\u00fcn, G. et al. A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. Blood 115, 5202\u20135213 (2010).","journal-title":"Blood"},{"key":"67783_CR16","unstructured":"scFOCAL v. v0.1.0-beta (Zenodo, 2025)."},{"key":"67783_CR17","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1038\/s41588-021-00926-8","volume":"53","author":"KC Johnson","year":"2021","unstructured":"Johnson, K. C. et al. Single-cell multimodal glioma analyses identify epigenetic regulators of cellular plasticity and environmental stress response. Nat. Genet. 53, 1456\u20131468 (2021).","journal-title":"Nat. Genet."},{"key":"67783_CR18","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1126\/science.aax0249","volume":"367","author":"GS Gulati","year":"2020","unstructured":"Gulati, G. S. et al. Single-cell transcriptional diversity is a hallmark of developmental potential. Science 367, 405\u2013411 (2020).","journal-title":"Science"},{"key":"67783_CR19","doi-asserted-by":"publisher","unstructured":"Rodriguez-Blanco, J. et al. Triptolide and its prodrug Minnelide target high-risk MYC-amplified medulloblastoma in preclinical models. J. Clin. Invest. 134 https:\/\/doi.org\/10.1172\/jci171136 (2024).","DOI":"10.1172\/jci171136"},{"key":"67783_CR20","doi-asserted-by":"crossref","unstructured":"Jermakowicz, A. M. et al. In silico drug sensitivity predicts subgroup-specific therapeutics in medulloblastoma patients. Sci Rep. 15, 42373 (2025)","DOI":"10.1038\/s41598-025-26411-4"},{"key":"67783_CR21","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/nm.4306","volume":"23","author":"SM Corsello","year":"2017","unstructured":"Corsello, S. M. et al. The Drug Repurposing Hub: a next-generation drug library and information resource. Nat. Med. 23, 405\u2013408 (2017).","journal-title":"Nat. Med."},{"key":"67783_CR22","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s11060-016-2285-8","volume":"131","author":"C Kurokawa","year":"2017","unstructured":"Kurokawa, C. et al. Alisertib demonstrates significant antitumor activity in bevacizumab resistant, patient derived orthotopic models of glioblastoma. J. Neuro-Oncol. 131, 41\u201348 (2017).","journal-title":"J. Neuro-Oncol."},{"key":"67783_CR23","doi-asserted-by":"publisher","first-page":"839","DOI":"10.2217\/nnm.14.1","volume":"9","author":"E Locatelli","year":"2014","unstructured":"Locatelli, E. et al. Targeted delivery of silver nanoparticles and alisertib: in vitro and in vivo synergistic effect against glioblastoma. Nanomedicine 9, 839\u2013849 (2014).","journal-title":"Nanomedicine"},{"key":"67783_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25501-x","volume":"12","author":"TTT Nguyen","year":"2021","unstructured":"Nguyen, T. T. T. et al. Aurora kinase A inhibition reverses the Warburg effect and elicits unique metabolic vulnerabilities in glioblastoma. Nat. Commun. 12, 5203 (2021).","journal-title":"Nat. Commun."},{"key":"67783_CR25","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/cdd.2008.156","volume":"16","author":"G Amabile","year":"2009","unstructured":"Amabile, G. et al. The Aurora B kinase activity is required for the maintenance of the differentiated state of murine myoblasts. Cell Death Differ. 16, 321\u2013330 (2009).","journal-title":"Cell Death Differ."},{"key":"67783_CR26","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/cac2.12125","volume":"41","author":"A Chen","year":"2021","unstructured":"Chen, A. et al. CRISPR\/Cas9 screening identifies a kinetochore-microtubule dependent mechanism for Aurora-A inhibitor resistance in breast cancer. Cancer Commun. 41, 121\u2013139 (2021).","journal-title":"Cancer Commun."},{"key":"67783_CR27","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s00109-020-01895-x","volume":"98","author":"T De Almeida Magalh\u00e3es","year":"2020","unstructured":"De Almeida Magalh\u00e3es, T. et al. The therapeutic potential of Aurora kinases targeting in glioblastoma: from preclinical research to translational oncology. J. Mol. Med. 98, 495\u2013512 (2020).","journal-title":"J. Mol. Med."},{"key":"67783_CR28","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.molcel.2013.08.022","volume":"51","author":"A Frangini","year":"2013","unstructured":"Frangini, A. et al. The aurora B kinase and the polycomb protein Ring1B combine to regulate active promoters in quiescent lymphocytes. Mol. Cell 51, 647\u2013661 (2013).","journal-title":"Mol. Cell"},{"key":"67783_CR29","doi-asserted-by":"publisher","first-page":"6939","DOI":"10.1073\/pnas.0900833106","volume":"106","author":"J Fu","year":"2009","unstructured":"Fu, J., Bian, M., Liu, J., Jiang, Q. & Zhang, C. A single amino acid change converts Aurora-A into Aurora-B-like kinase in terms of partner specificity and cellular function. Proc. Natl. Acad. Sci. USA 106, 6939\u20136944 (2009).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"67783_CR30","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.ceb.2018.12.007","volume":"58","author":"H Funabiki","year":"2019","unstructured":"Funabiki, H. Correcting aberrant kinetochore microtubule attachments: a hidden regulation of Aurora B on microtubules. Curr. Opin. Cell Biol. 58, 34\u201341 (2019).","journal-title":"Curr. Opin. Cell Biol."},{"key":"67783_CR31","doi-asserted-by":"publisher","first-page":"4515","DOI":"10.3892\/ol.2016.5261","volume":"12","author":"J Gan","year":"2016","unstructured":"Gan, J. et al. RNA interference targeting Aurora-A sensitizes glioblastoma cells to temozolomide chemotherapy. Oncol. Lett. 12, 4515\u20134523 (2016).","journal-title":"Oncol. Lett."},{"key":"67783_CR32","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1074\/mcp.M112.021030","volume":"11","author":"AJ Guise","year":"2012","unstructured":"Guise, A. J., Greco, T. M., Zhang, I. Y., Yu, F. & Cristea, I. M. Aurora B-dependent regulation of class IIa histone deacetylases by mitotic nuclear localization signal phosphorylation. Mol. Cell Proteom. 11, 1220\u20131229 (2012).","journal-title":"Mol. Cell Proteom."},{"key":"67783_CR33","doi-asserted-by":"publisher","first-page":"4269","DOI":"10.1007\/s00018-018-2780-5","volume":"75","author":"SSL Gwee","year":"2018","unstructured":"Gwee, S. S. L. et al. Aurora kinase B regulates axonal outgrowth and regeneration in the spinal motor neurons of developing zebrafish. Cell. Mol. Life Sci. 75, 4269\u20134285 (2018).","journal-title":"Cell. Mol. Life Sci."},{"key":"67783_CR34","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1158\/1535-7163.MCT-17-0089","volume":"16","author":"S Islam","year":"2017","unstructured":"Islam, S. et al. Disruption of aneuploidy and senescence induced by aurora inhibition promotes intrinsic apoptosis in double hit or double expressor diffuse large B-cell lymphomas. Mol. Cancer Ther. 16, 2083\u20132093 (2017).","journal-title":"Mol. Cancer Ther."},{"key":"67783_CR35","doi-asserted-by":"publisher","first-page":"27","DOI":"10.5507\/bp.2008.004","volume":"152","author":"M Kollareddy","year":"2008","unstructured":"Kollareddy, M., Dzubak, P., Zheleva, D. & Hajduch, M. Aurora kinases: structure, functions and their association with cancer. Biomed. Pap. 152, 27\u201333 (2008).","journal-title":"Biomed. Pap."},{"key":"67783_CR36","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1038\/ncb0909-1053","volume":"11","author":"GK Lefkowitz","year":"2009","unstructured":"Lefkowitz, G. K. & Gleeson, J. G. Aurora A moonlights in neurite extension. Nat. Cell Biol. 11, 1053\u20131054 (2009).","journal-title":"Nat. Cell Biol."},{"key":"67783_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/srep30213","volume":"6","author":"S Loponte","year":"2016","unstructured":"Loponte, S. et al. Dynamic phosphorylation of Histone Deacetylase 1 by Aurora kinases during mitosis regulates zebrafish embryos development. Sci. Rep. 6, 30213 (2016).","journal-title":"Sci. Rep."},{"key":"67783_CR38","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1182\/bloodadvances.2019000232","volume":"3","author":"C Murga-Zamalloa","year":"2019","unstructured":"Murga-Zamalloa, C., Inamdar, K. V. & Wilcox, R. A. The role of aurora A and polo-like kinases in high-risk lymphomas. Blood Adv. 3, 1778\u20131787 (2019).","journal-title":"Blood Adv."},{"key":"67783_CR39","doi-asserted-by":"publisher","first-page":"4977","DOI":"10.1128\/MCB.25.12.4977-4992.2005","volume":"25","author":"HG Nguyen","year":"2005","unstructured":"Nguyen, H. G., Chinnappan, D., Urano, T. & Ravid, K. Mechanism of Aurora-B degradation and its dependency on intact KEN and A-boxes: identification of an aneuploidy-promoting property. Mol. Cell Biol. 25, 4977\u20134992 (2005).","journal-title":"Mol. Cell Biol."},{"key":"67783_CR40","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1158\/0008-5472.CAN-19-1479","volume":"80","author":"J Ommer","year":"2020","unstructured":"Ommer, J. et al. Aurora A kinase inhibition destabilizes PAX3-FOXO1 and MYCN and synergizes with navitoclax to induce rhabdomyosarcoma cell death. Cancer Res. 80, 832\u2013842 (2020).","journal-title":"Cancer Res."},{"key":"67783_CR41","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1083\/jcb.201012061","volume":"193","author":"OV Plotnikova","year":"2011","unstructured":"Plotnikova, O. V., Pugacheva, E. N. & Golemis, E. A. Aurora A kinase activity influences calcium signaling in kidney cells. J. Cell Biol. 193, 1021\u20131032 (2011).","journal-title":"J. Cell Biol."},{"key":"67783_CR42","doi-asserted-by":"publisher","first-page":"128614","DOI":"10.1016\/j.bmcl.2022.128614","volume":"61","author":"MJ Rybin","year":"2022","unstructured":"Rybin, M. J. et al. A dual aurora and lim kinase inhibitor reduces glioblastoma proliferation and invasion. Bioorg. Med. Chem. Lett. 61, 128614 (2022).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"67783_CR43","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1021\/ml500409n","volume":"6","author":"TB Sells","year":"2015","unstructured":"Sells, T. B. et al. MLN8054 and Alisertib (MLN8237): discovery of selective oral aurora A inhibitors. ACS Med. Chem. Lett. 6, 630\u2013634 (2015).","journal-title":"ACS Med. Chem. Lett."},{"key":"67783_CR44","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.radonc.2018.12.019","volume":"132","author":"A Song","year":"2019","unstructured":"Song, A. et al. Phase I trial of alisertib with concurrent fractionated stereotactic re-irradiation for recurrent high grade gliomas. Radiother. Oncol. 132, 135\u2013141 (2019).","journal-title":"Radiother. Oncol."},{"key":"67783_CR45","doi-asserted-by":"publisher","first-page":"11050","DOI":"10.1523\/JNEUROSCI.5664-11.2012","volume":"32","author":"T Takitoh","year":"2012","unstructured":"Takitoh, T. et al. Activation of aurora-A is essential for neuronal migration via modulation of microtubule organization. J. Neurosci. 32, 11050\u201311066 (2012).","journal-title":"J. Neurosci."},{"key":"67783_CR46","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.3892\/ijo.2017.3880","volume":"50","author":"R Wang","year":"2017","unstructured":"Wang, R. et al. UBE2C induces EMT through Wnt\/\u03b2-catenin and PI3K\/Akt signaling pathways by regulating phosphorylation levels of Aurora-A. Int. J. Oncol. 50, 1116\u20131126 (2017).","journal-title":"Int. J. Oncol."},{"key":"67783_CR47","doi-asserted-by":"publisher","unstructured":"Willems, E. et al. The functional diversity of Aurora kinases: a comprehensive review. Cell Division 13 https:\/\/doi.org\/10.1186\/s13008-018-0040-6 (2018).","DOI":"10.1186\/s13008-018-0040-6"},{"key":"67783_CR48","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s11523-016-0457-2","volume":"12","author":"E Willems","year":"2017","unstructured":"Willems, E., Lombard, A., Dedobbeleer, M., Goffart, N. & Rogister, B. The unexpected roles of aurora A kinase in gliobastoma recurrences. Target. Oncol. 12, 11\u201318 (2017).","journal-title":"Target. Oncol."},{"key":"67783_CR49","doi-asserted-by":"crossref","unstructured":"Ding, Y.H. et al. Alisertib, an Aurora kinase A inhibitor, induces apoptosis and autophagy but inhibits epithelial to mesenchymal transition in human epithelial ovarian cancer cells. Drug Des Devel Ther. 9, 425\u2013464 (2015).","DOI":"10.2147\/DDDT.S74062"},{"key":"67783_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01305-3","volume":"20","author":"R Du","year":"2021","unstructured":"Du, R., Huang, C., Liu, K., Li, X. & Dong, Z. Targeting AURKA in cancer: molecular mechanisms and opportunities for cancer therapy. Mol. Cancer 20, 15 (2021).","journal-title":"Mol. Cancer"},{"key":"67783_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-021-00894-y","volume":"13","author":"W Zhao","year":"2021","unstructured":"Zhao, W. et al. Deconvolution of cell type-specific drug responses in human tumor tissue with single-cell RNA-seq. Genome Med. 13, 82 (2021).","journal-title":"Genome Med."},{"key":"67783_CR52","doi-asserted-by":"publisher","unstructured":"Houweling, M. et al. Screening of predicted synergistic multi-target therapies in glioblastoma identifies new treatment strategies. Neuro-Oncol. Adv. 5 https:\/\/doi.org\/10.1093\/noajnl\/vdad073 (2023).","DOI":"10.1093\/noajnl\/vdad073"},{"key":"67783_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-54858-y","volume":"16","author":"K Desai","year":"2025","unstructured":"Desai, K. et al. OLIG2 mediates a rare targetable stem cell fate transition in sonic hedgehog medulloblastoma. Nat. Commun. 16, 1092 (2025).","journal-title":"Nat. Commun."},{"key":"67783_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-54861-3","volume":"16","author":"Y Li","year":"2025","unstructured":"Li, Y. et al. Suppressing recurrence in Sonic Hedgehog subgroup medulloblastoma using the OLIG2 inhibitor CT-179. Nat. Commun. 16, 1091 (2025).","journal-title":"Nat. Commun."},{"key":"67783_CR55","doi-asserted-by":"publisher","unstructured":"Li, Y. et al. Preventing recurrence in Sonic Hedgehog Subgroup Medulloblastoma using the OLIG2 inhibitor CT-179. Res. Sq. https:\/\/doi.org\/10.21203\/rs.3.rs-2949436\/v1 (2023).","DOI":"10.21203\/rs.3.rs-2949436\/v1"},{"key":"67783_CR56","doi-asserted-by":"publisher","first-page":"1129434","DOI":"10.3389\/fnins.2023.1129434","volume":"17","author":"JI Szu","year":"2023","unstructured":"Szu, J. I., Tsigelny, I. F., Wojcinski, A. & Kesari, S. Biological functions of the Olig gene family in brain cancer and therapeutic targeting. Front. Neurosci. 17, 1129434 (2023).","journal-title":"Front. Neurosci."},{"key":"67783_CR57","doi-asserted-by":"publisher","first-page":"4278","DOI":"10.1158\/1078-0432.CCR-22-0527","volume":"28","author":"Z Xu","year":"2022","unstructured":"Xu, Z. et al. OLIG2 is a determinant for the relapse of MYC-amplified medulloblastoma. Clin. Cancer Res. 28, 4278\u20134291 (2022).","journal-title":"Clin. Cancer Res."},{"key":"67783_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-30376-y","volume":"8","author":"S Kapoor","year":"2018","unstructured":"Kapoor, S., Srivastava, S. & Panda, D. Indibulin dampens microtubule dynamics and produces synergistic antiproliferative effect with vinblastine in MCF-7 cells: Implications in cancer chemotherapy. Sci. Rep. 8, 12363 (2018).","journal-title":"Sci. Rep."},{"key":"67783_CR59","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s10637-009-9244-6","volume":"28","author":"RL Oostendorp","year":"2010","unstructured":"Oostendorp, R. L. et al. Dose-finding and pharmacokinetic study of orally administered indibulin (D-24851) to patients with advanced solid tumors. Invest. New Drugs 28, 163\u2013170 (2010).","journal-title":"Invest. New Drugs"},{"key":"67783_CR60","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1158\/0008-5472.CAN-08-1342","volume":"69","author":"A Wienecke","year":"2009","unstructured":"Wienecke, A. & Bacher, G. Indibulin, a novel microtubule inhibitor, discriminates between mature neuronal and nonneuronal tubulin. Cancer Res. 69, 171\u2013177 (2009).","journal-title":"Cancer Res."},{"key":"67783_CR61","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1358\/dot.2006.42.4.968648","volume":"42","author":"B Ramaswamy","year":"2006","unstructured":"Ramaswamy, B. & Puhalla, S. Docetaxel: a tubulin-stabilizing agent approved for the management of several solid tumors. Drugs Today 42, 265\u2013279 (2006).","journal-title":"Drugs Today"},{"key":"67783_CR62","doi-asserted-by":"crossref","unstructured":"Chowdary, R. et al. OrthologAL: a Shiny application for quality-aware humanization of non-human pre-clinical high-dimensional gene expression data. Bioinformatics. 41, btaf311 (2025).","DOI":"10.1093\/bioinformatics\/btaf311"},{"key":"67783_CR63","doi-asserted-by":"crossref","unstructured":"Sinha, S. et al. PERCEPTION predicts patient response and resistance to treatment using single-cell transcriptomics of their tumors. Nat Cancer. 5, 938\u2013952 (2024).","DOI":"10.1038\/s43018-024-00756-7"},{"key":"67783_CR64","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1038\/s41588-018-0209-6","volume":"50","author":"J-K Lee","year":"2018","unstructured":"Lee, J.-K. et al. Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy. Nat. Genet. 50, 1399\u20131411 (2018).","journal-title":"Nat. Genet."},{"key":"67783_CR65","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-022-00294-4","volume":"6","author":"JH Park","year":"2022","unstructured":"Park, J. H. et al. A single-cell based precision medicine approach using glioblastoma patient-specific models. npj Precis. Oncol. 6, 55 (2022).","journal-title":"npj Precis. Oncol."},{"key":"67783_CR66","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-9-205","volume":"9","author":"S Courapied","year":"2010","unstructured":"Courapied, S. et al. Regulation of the Aurora-A gene following topoisomerase I inhibition: implication of the Myc transcription factor. Mol. Cancer 9, 205 (2010).","journal-title":"Mol. Cancer"},{"key":"67783_CR67","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1126\/science.1254257","volume":"344","author":"AP Patel","year":"2014","unstructured":"Patel, A. P. et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 344, 1396\u20131401 (2014).","journal-title":"Science"},{"key":"67783_CR68","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/s41586-021-03796-6","volume":"596","author":"Y Oren","year":"2021","unstructured":"Oren, Y. et al. Cycling cancer persister cells arise from lineages with distinct programs. Nature 596, 576\u2013582 (2021).","journal-title":"Nature"},{"key":"67783_CR69","doi-asserted-by":"publisher","unstructured":"Ocasio, J. et al. scRNA-seq in medulloblastoma shows cellular heterogeneity and lineage expansion support resistance to SHH inhibitor therapy. Nat. Commun. 10 https:\/\/doi.org\/10.1038\/s41467-019-13657-6 (2019)","DOI":"10.1038\/s41467-019-13657-6"},{"key":"67783_CR70","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41586-019-1775-1","volume":"576","author":"FP Barthel","year":"2019","unstructured":"Barthel, F. P. et al. Longitudinal molecular trajectories of diffuse glioma in adults. Nature 576, 112\u2013120 (2019).","journal-title":"Nature"},{"key":"67783_CR71","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1093\/neuonc\/noy020","volume":"20","author":"TG Consortium","year":"2018","unstructured":"Consortium, T. G. Glioma through the looking GLASS: molecular evolution of diffuse gliomas and the Glioma Longitudinal Analysis Consortium. Neuro-Oncology 20, 873\u2013884 (2018).","journal-title":"Neuro-Oncology"},{"key":"67783_CR72","unstructured":"Varn, F. S. et al. GLASS Consortium et al. Glioma progression is shaped by genetic evolution and microenvironment interactions. Cell. 185, 2184\u20132199.e16 (2022)."},{"key":"67783_CR73","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-54750-9","volume":"15","author":"BL Myers","year":"2024","unstructured":"Myers, B. L. et al. Transcription factors ASCL1 and OLIG2 drive glioblastoma initiation and co-regulate tumor cell types and migration. Nat. Commun. 15, 10363 (2024).","journal-title":"Nat. Commun."},{"key":"67783_CR74","doi-asserted-by":"publisher","first-page":"3967","DOI":"10.1158\/0008-5472.CAN-23-4024","volume":"84","author":"G MacLeod","year":"2024","unstructured":"MacLeod, G. et al. Fitness screens map state-specific glioblastoma stem cell vulnerabilities. Cancer Res. 84, 3967\u20133983 (2024).","journal-title":"Cancer Res."},{"key":"67783_CR75","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1093\/neuonc\/noac173","volume":"25","author":"AB Lassman","year":"2023","unstructured":"Lassman, A. B. et al. Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: a phase III randomized clinical trial. Neuro-Oncology 25, 339\u2013350 (2023).","journal-title":"Neuro-Oncology"},{"key":"67783_CR76","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1093\/neuonc\/noab133","volume":"23","author":"BM Marin","year":"2021","unstructured":"Marin, B. M. et al. Heterogeneous delivery across the blood-brain barrier limits the efficacy of an EGFR-targeting antibody drug conjugate in glioblastoma. Neuro-Oncology 23, 2042\u20132053 (2021).","journal-title":"Neuro-Oncology"},{"key":"67783_CR77","doi-asserted-by":"publisher","first-page":"W449","DOI":"10.1093\/nar\/gku476","volume":"42","author":"Q Duan","year":"2014","unstructured":"Duan, Q. et al. LINCS Canvas Browser: interactive web app to query, browse and interrogate LINCS L1000 gene expression signatures. Nucleic Acids Res. 42, W449\u2013W460 (2014).","journal-title":"Nucleic Acids Res."},{"key":"67783_CR78","doi-asserted-by":"publisher","DOI":"10.1038\/npjsba.2016.15","volume":"2","author":"Q Duan","year":"2016","unstructured":"Duan, Q. et al. L1000CDS2: LINCS L1000 characteristic direction signatures search engine. npj Syst. Biol. Appl. 2, 16015 (2016).","journal-title":"npj Syst. Biol. Appl."},{"key":"67783_CR79","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13817-8","volume":"11","author":"E Almstedt","year":"2020","unstructured":"Almstedt, E. et al. Integrative discovery of treatments for high-risk neuroblastoma. Nat. Commun. 11, 71 (2020).","journal-title":"Nat. Commun."},{"key":"67783_CR80","doi-asserted-by":"crossref","unstructured":"He, W., McCoy, M.D., Riggins, R. B., Beckman, R. A. & Yeang, C.-H. Personalized cancer treatment strategies incorporating irreversible and reversible drug resistance mechanisms. npj Syst Biol Appl. 11, 70 (2025).","DOI":"10.1038\/s41540-025-00547-5"},{"key":"67783_CR81","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1124\/jpet.117.243477","volume":"363","author":"JK Laramy","year":"2017","unstructured":"Laramy, J. K. et al. Heterogeneous binding and central nervous system distribution of the multitargeted kinase inhibitor ponatinib restrict orthotopic efficacy in a patient-derived xenograft model of glioblastoma. J. Pharm. Exp. Ther. 363, 136\u2013147 (2017).","journal-title":"J. Pharm. Exp. Ther."},{"key":"67783_CR82","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/s41586-018-0744-4","volume":"564","author":"BA Biddy","year":"2018","unstructured":"Biddy, B. A. et al. Single-cell mapping of lineage and identity in direct reprogramming. Nature 564, 219\u2013224 (2018).","journal-title":"Nature"},{"key":"67783_CR83","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1038\/s41596-019-0247-2","volume":"15","author":"W Kong","year":"2020","unstructured":"Kong, W. et al. CellTagging: combinatorial indexing to simultaneously map lineage and identity at single-cell resolution. Nat. Protoc. 15, 750\u2013772 (2020).","journal-title":"Nat. Protoc."},{"key":"67783_CR84","doi-asserted-by":"publisher","unstructured":"Jermakowicz, A. M. et al. The novel BET inhibitor UM-002 reduces glioblastoma cell proliferation and invasion. Sci. Rep. 11 https:\/\/doi.org\/10.1038\/s41598-021-02584-6 (2021).","DOI":"10.1038\/s41598-021-02584-6"},{"key":"67783_CR85","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1158\/1078-0432.CCR-19-0909","volume":"26","author":"RA Vaubel","year":"2020","unstructured":"Vaubel, R. A. et al. Genomic and phenotypic characterization of a broad panel of patient-derived xenografts reflects the diversity of glioblastoma. Clin. Cancer Res. 26, 1094\u20131104 (2020).","journal-title":"Clin. Cancer Res."},{"key":"67783_CR86","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.1523\/JNEUROSCI.06-10-03044.1986","volume":"6","author":"J Huettner","year":"1986","unstructured":"Huettner, J. & Baughman, R. Primary culture of identified neurons from the visual cortex of postnatal rats. J. Neurosci. 6, 3044\u20133060 (1986).","journal-title":"J. Neurosci."},{"key":"67783_CR87","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/nbt.4096","volume":"36","author":"A Butler","year":"2018","unstructured":"Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol. 36, 411\u2013420 (2018).","journal-title":"Nat. Biotechnol."},{"key":"67783_CR88","doi-asserted-by":"publisher","unstructured":"Hafemeister, C. & Satija, R. Normalization and variance stabilization of single-cell RNA-seq data using regularized negative binomial regression. Genome Biol. 20 https:\/\/doi.org\/10.1186\/s13059-019-1874-1 (2019).","DOI":"10.1186\/s13059-019-1874-1"},{"key":"67783_CR89","unstructured":"Hao, Y. et al. Integrated Analysis of Multimodal Single-cell Data (Cold Spring Harbor Laboratory, 2020)."},{"key":"67783_CR90","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nbt.3192","volume":"33","author":"R Satija","year":"2015","unstructured":"Satija, R., Farrell, J. A., Gennert, D., Schier, A. F. & Regev, A. Spatial reconstruction of single-cell gene expression data. Nat. Biotechnol. 33, 495\u2013502 (2015).","journal-title":"Nat. Biotechnol."},{"key":"67783_CR91","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1016\/j.cell.2019.05.031","volume":"177","author":"T Stuart","year":"2019","unstructured":"Stuart, T. et al. Comprehensive integration of single-cell data. Cell 177, 1888\u20131902.e1821 (2019).","journal-title":"Cell"},{"key":"67783_CR92","doi-asserted-by":"publisher","unstructured":"Finak, G. et al. MAST: a flexible statistical framework for assessing transcriptional changes and characterizing heterogeneity in single-cell RNA sequencing data. Genome Biol. 16 https:\/\/doi.org\/10.1186\/s13059-015-0844-5 (2015).","DOI":"10.1186\/s13059-015-0844-5"},{"key":"67783_CR93","doi-asserted-by":"publisher","unstructured":"Foroutan, M. et al. Single sample scoring of molecular phenotypes. BMC Bioinform. 19 https:\/\/doi.org\/10.1186\/s12859-018-2435-4 (2018).","DOI":"10.1186\/s12859-018-2435-4"},{"key":"67783_CR94","unstructured":"pheatmap: Pretty Heatmaps v. 1.0.12 (2019)."},{"key":"67783_CR95","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-60031-8","volume":"14","author":"AM Jermakowicz","year":"2024","unstructured":"Jermakowicz, A. M. et al. RAPID resistance to BET inhibitors is mediated by FGFR1 in glioblastoma. Sci. Rep. 14, 9284 (2024).","journal-title":"Sci. Rep."},{"key":"67783_CR96","doi-asserted-by":"publisher","first-page":"e2005970","DOI":"10.1371\/journal.pbio.2005970","volume":"16","author":"C McQuin","year":"2018","unstructured":"McQuin, C. et al. CellProfiler 3.0: Next-generation image processing for biology. PLoS Biol. 16, e2005970 (2018).","journal-title":"PLoS Biol."},{"key":"67783_CR97","first-page":"100141","volume":"2","author":"T Wu","year":"2021","unstructured":"Wu, T. et al. clusterProfiler 4.0: a universal enrichment tool for interpreting omics data. Innovation 2, 100141 (2021).","journal-title":"Innovation"},{"key":"67783_CR98","doi-asserted-by":"publisher","first-page":"3292","DOI":"10.1038\/s41596-024-01020-z","volume":"19","author":"S Xu","year":"2024","unstructured":"Xu, S. et al. Using clusterProfiler to characterize multiomics data. Nat. Protoc. 19, 3292\u20133320 (2024).","journal-title":"Nat. Protoc."},{"key":"67783_CR99","first-page":"100722","volume":"5","author":"G Yu","year":"2024","unstructured":"Yu, G. Thirteen years of clusterProfiler. Innovation 5, 100722 (2024).","journal-title":"Innovation"},{"key":"67783_CR100","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu, G., Wang, L. G., Han, Y. & He, Q. Y. clusterProfiler: an R package for comparing biological themes among gene clusters. Omics 16, 284\u2013287 (2012).","journal-title":"Omics"},{"key":"67783_CR101","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/j.cell.2017.10.049","volume":"171","author":"A Subramanian","year":"2017","unstructured":"Subramanian, A. et al. A next generation connectivity map: L1000 platform and the first 1,000,000 profiles. Cell 171, 1437\u20131452.e1417 (2017).","journal-title":"Cell"},{"key":"67783_CR102","unstructured":"_factoextra: extract and visualize the results of multivariate data analyses_. v. 1.0.7 (2020)."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67783-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67783-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67783-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T10:03:23Z","timestamp":1767780203000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67783-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":102,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["67783"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-67783-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2025.05.15.654044","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,7]]},"assertion":[{"value":"24 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"99"}}